TOP TEN perturbations for 11759610_at (Homo sapiens)

Organism: Homo sapiens
Gene: 11759610_at
Selected probe(set): 236892_s_at
Platform: Affymetrix Human Genome U133 Plus 2.0 Array

Expression of 11759610_at (236892_s_at) across 5880 perturbations tested by GENEVESTIGATOR:

stem cell differentiation study 41 (hES-T3 EB) / undifferentiated hES-T3 cell sample

Relative Expression (log2-ratio):5.688601
Number of Samples:2 / 3
Experimental stem cell differentiation study 41 (hES-T3 EB)
Sample of embryonic bodies (EB) differentiated from human embryonic stem cells T3 with female karyotype.
Control undifferentiated hES-T3 cell sample
Undifferentiated human embryonic stem cells T3.

bone cancer study 1 (PDX; chondrosarcoma, NOS; primary) / bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)

Relative Expression (log2-ratio):-5.5553837
Number of Samples:2 / 2
Experimental bone cancer study 1 (PDX; chondrosarcoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary chondrosarcoma, NOS of the bone (subcutaneously implanted).
Control bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary myxoid chondrosarcoma of the bone (subcutaneously implanted).

bone cancer study 1 (PDX; chondroblastic osteosarcoma; primary) / bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)

Relative Expression (log2-ratio):-5.4936934
Number of Samples:2 / 2
Experimental bone cancer study 1 (PDX; chondroblastic osteosarcoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary chondroblastic osteosarcoma of the bone (subcutaneously implanted).
Control bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary myxoid chondrosarcoma of the bone (subcutaneously implanted).

bone cancer study 1 (PDX; osteosarcoma, NOS; primary) / bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)

Relative Expression (log2-ratio):-5.342065
Number of Samples:2 / 2
Experimental bone cancer study 1 (PDX; osteosarcoma, NOS; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary osteosarcoma, NOS of the bone (subcutaneously implanted).
Control bone cancer study 1 (PDX; myxoid chondrosarcoma; primary)
Patient-derived xenograft (PDX) samples generated in female athymic nude mice from patients with primary myxoid chondrosarcoma of the bone (subcutaneously implanted).

stem cell differentiation study 41 (T3pi) / undifferentiated hES-T3 cell sample

Relative Expression (log2-ratio):4.9464087
Number of Samples:2 / 3
Experimental stem cell differentiation study 41 (T3pi)
Sample of pancreatic islet-like cell clusters differentiated from human embryonic stem cells T3 with female karyotype.
Control undifferentiated hES-T3 cell sample
Undifferentiated human embryonic stem cells T3.

SW620 / SW480

Relative Expression (log2-ratio):-4.686945
Number of Samples:62 / 63
Experimental SW620
Human metastatic cancer cell line derived from the lymph node of a patient with adenocarcinoma of the colon. Synonyms:SW-620; SW 620; SW.620 Cellosaurus code:
Control SW480
Human primary cancer cell line derived from the colon of a male patient with adenocarcinoma. Synonyms:SW-480; SW 480; SW480E Cellosaurus code:

pancreatic islet study 3 (expanded; PPRF) / normal pancreatic islet sample

Relative Expression (log2-ratio):4.4955707
Number of Samples:2 / 7
Experimental pancreatic islet study 3 (expanded; PPRF)
Human pancreatic islets were isolated from a cadaveric donor. The population was 70% pure in mature islets, which was determined by dithizone staining. Islets cells were expanded according to Pharmaceutical Production Research Facility Protocol (PPRF) for 6 weeks. Expansion phase: Approximately 2,500 islet equivalents were seeded onto 75-cm2 fibronectin-coated tissue culture-treated flasks in a proprietary serum-free medium (PPRF medium). The serum-free PPRF medium was supplemented with 30% serum-free mesenchymal-conditioned medium. When the cell migration resulted in the formation of large-size colonies, the cells were harvested by trypsinization and replated into new tissue culture flasks. Once the cells reached near confluence (80–90%) in monolayer, they were trypsinized, counted, and subcultured at a density of 5,000 cells per cm2. Thereafter, cells were serially passaged using the same protocol.
Control normal pancreatic islet sample
Pancreatic islets were obtained from seven donors aged between 37 and 70 years and body mass index between 22 and 27. Functional islets were cultured in CMRL 1066 supplemented with 10% FCS, 1% glutamine, 5.6 mM glucose, 1 mM HEPES, 110 U/ml penicillin, and 110 g/ml streptomycin for 7 days or immediately processed after isolation.

pancreatic islet study 3 (re-differentiated; Whittier) / normal pancreatic islet sample

Relative Expression (log2-ratio):4.4606185
Number of Samples:2 / 7
Experimental pancreatic islet study 3 (re-differentiated; Whittier)
Human pancreatic islets were from 2 male donors (46 and 54 years old, body mass index 21kg/m2 and 31.6kg/m2). Islets cells were expanded for 4 weeks and re-differentiated for 1 week according to Whittier protocol. Re-differentiation phase: After four passages (1 month expansion), cells were dispersed with Versene and cultured in serum-free CMRL-1066 medium supplemented with insulin (10 g/ml), transferrin (5.5 g/ml), sodium selenite (6.7ng/ml). After 1 week of culture on HTB-9-coated plates, cells were harvested and forced to reaggregate overnight.
Control normal pancreatic islet sample
Pancreatic islets were obtained from seven donors aged between 37 and 70 years and body mass index between 22 and 27. Functional islets were cultured in CMRL 1066 supplemented with 10% FCS, 1% glutamine, 5.6 mM glucose, 1 mM HEPES, 110 U/ml penicillin, and 110 g/ml streptomycin for 7 days or immediately processed after isolation.

pancreatic islet study 3 (re-differentiated; PPRF; 2d) / normal pancreatic islet sample

Relative Expression (log2-ratio):4.1388583
Number of Samples:2 / 7
Experimental pancreatic islet study 3 (re-differentiated; PPRF; 2d)
Human pancreatic islets were isolated from a cadaveric donor. The population was 70% pure in mature islets, which was determined by dithizone staining. Islets cells were expanded for 6 weeks and re-differentiated for 2 days according to Pharmaceutical Production Research Facility (PPRF) Protocol. Re-differentiation phase: For induction of expanded cells to differentiate into islet-like cell clusters, the cells were seeded into 60 mm ultra-low attachment dishes in serum-free CMRL-1066 supplemented with 4 mM L-glutamine, 1% BSA, insulin (10 g/ml), transferrin (5.5 g/ml), sodium selenite (6.7ng/ml), and 1% antibiotic antimycotic solution at a density of 6.0 x 10EXP6 cells per dish. The induction medium was further added with islet neogenesis-associated protein (INGAP) peptide at a concentration of 1.0ug/ml.
Control normal pancreatic islet sample
Pancreatic islets were obtained from seven donors aged between 37 and 70 years and body mass index between 22 and 27. Functional islets were cultured in CMRL 1066 supplemented with 10% FCS, 1% glutamine, 5.6 mM glucose, 1 mM HEPES, 110 U/ml penicillin, and 110 g/ml streptomycin for 7 days or immediately processed after isolation.

embryonic development study 1 (8wk) / embryonic development study 1 (4wk)

Relative Expression (log2-ratio):-4.032216
Number of Samples:3 / 3
Experimental embryonic development study 1 (8wk)
Human embryos at 8th week after fertilization. Embryos were obtained after therapeutic termination of pregnancy with mifepristone.
Control embryonic development study 1 (4wk)
Human embryos at 4th week after fertilization. Embryos were obtained after therapeutic termination of pregnancy with mifepristone.